Back

ResearchAndMarkets adds CD47 and SIRP-alpha immunotherapy pipeline report

Verifying
  • ResearchAndMarkets.com added a report on CD47 and SIRP-alpha targeted immunotherapy programs.
  • More than 20 candidates targeting the pathway have entered clinical development.
  • The report covers development phases, modalities, clinical progress and competitive differentiation factors.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.